Osteonecrosis of the Jaw Lawsuit Over Zometa Results in Defense Verdict

A New Jersey jury has returned a defense verdict in a Zometa lawsuit brought by a woman who alleged that the bone-strengthening cancer drug caused her to suffer a painful and permanent jaw injury, known as osteonecrosis of the jaw

The verdict was handed down on Wednesday in a case brought by Jane Bessemer, 73, who accused Novartis, the manufacturer of Zometa, of failing to warn about the increased risk of jaw problems associated with the drug. The case is the second osteonecrosis of the jaw lawsuit over Zometa to go to trial, after a prior lawsuit ended in a $3.2 million verdict in October.

Zometa (zoledronic acid) is a treatment that is used to reduce bone complications associated with multiple myeloma and bone metastases from solid tumors. Although it is used to strengthen bones, it is part of a class of medications known as bisphosphonates, which have been associated with an increased risk of osteonecrosis of the jaw. The debilitating and painful condition causes decay or death of the jaw bone, often resulting in the need for surgery to remove portions of the jaw.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Bessemer took Zometa and Aredia, a similar drug, while she battled with breast cancer. While she claimed that her ONJ came from the use of those drugs, Novartis lawyers argued that Bessemer suffered from a bone infection known as osteomyelitis, not ONJ. They also argued that Zometa carried adequate warnings about the risk of jaw decay.

There are currently about 150 lawsuits over Zometa pending in New Jersey state court and another 550 that are part of a multidistrict litigation (MDL) centralized and consolidated in U.S. District Court in Nashville, Tennessee.

The Zometa product liability claims are similar to more than 900 Fosamax jaw necrosis lawsuits that are pending against Merck & Co. over their oral bisphosphonate medication. Fosamax is used to reduce the risk of bone fractures associated with osteoporosis, but it has also been linked to an increased risk of jaw osteonecrosis.

Earlier this year, a federal jury awarded $8 million for osteonecrosis of the jaw from Fosamax, but that amount was later reduced to $1.5 million after the judge determined that the jury’s award included excessive compensation for the jaw injury suffered by that plaintiff.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Indivior Files Motion to Dismiss Suboxone Failure to Warn Lawsuits Based on Federal Preemption
Indivior Files Motion to Dismiss Suboxone Failure to Warn Lawsuits Based on Federal Preemption (Posted today)

Indivior has filed a motion to dismiss Suboxone lawsuits, claiming that allegations of failure to warn and design defect are preempted by federal laws that would protect the company from tooth decay injury claims.